Urinary Bladder Neoplasms: all 1,649 studies

Page 12 of 17. Open to participants first (427), then studies with results posted, then the rest; newest registration first within each.

• A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint InhibitorsActive, not recruitingNCT03693014Phase 2
• Use of Immediate Hyperthermic Intravesical Chemotherapy Following TURBTCompletedNCT03689478Not applicable
• Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial CancerActive, not recruitingNCT03682068Phase 3
• Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial)CompletedNCT03674424Phase 2
• Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG TreatmentCompletedNCT03672240Phase 1/2
• A Multi-National Study In Bladder Cancer Patients to Detect Recurrences After TURB (Trans-urethral Resection of the Bladder) Earlier With the Xpert Bladder Cancer Monitor Assay (ANTICIPATE X)CompletedNCT03664258
• A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder CancerCompletedNCT03661320Phase 3
• Effects of a Neuroscience-based Technique on Cancer Patients Announced of a Palliative Disease Progression and PartnersTerminatedNCT03652298Phase 2
• PRS-343 in Combination With Atezolizumab in HER2-Positive Solid TumorsCompletedNCT03650348Phase 1
• Mass Spectrometry in Single Bladder Cancer CellsCompletedNCT03639090
• Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder CancerStatus unknownNCT03620435Phase 2
• Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder CancerActive, not recruitingNCT03601455Phase 2
• The Difference of Two Year Recurrence Rate According to Anesthetic Method During Transurethral Resection of Bladder Mass in Patients With Non-muscle Invasive Bladder Cancer: Prospective, Randomized, Clinical Phase II StudyStatus unknownNCT03597087Not applicable
• The Potential Role Of MicroRNA-155 And Telomerase Reverse Transcriptase In Diagnosis Of Non-Muscle Invasive Bladder Cancer And Their Pathological CorrelationCompletedNCT03591367Not applicable
• Patient-reported Outcomes in Bladder CancerCompletedNCT03584659Not applicable
• The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder CancerStatus unknownNCT03577132Not applicable
• Genomic Imprinting Testing for Diagnosis of Bladder CancerStatus unknownNCT03563443
• A First-in-Human Study of alpha1H in Patients With Non-muscle Invasive Bladder CancerStatus unknownNCT03560479Phase 1/2
• sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder CancerWithdrawnNCT03552796Phase 1
• Prevention and Management of Intravesical BCG-related Lower Urinary Tract SymptomsTerminatedNCT03549650Phase 2
• Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)CompletedNCT03534492Phase 2
• Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the BladderStatus unknownNCT03529890Phase 2
• A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for ChemotherapyActive, not recruitingNCT03520491Phase 2
• Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder CancerTerminatedNCT03518320Phase 1
• Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer ChemopreventionWithdrawnNCT03517995Phase 2
• HIPEC After Radical Cystectomy for High Risk Bladder CancerCompletedNCT03514888Not applicable
• The Effect of Goal-directed Hemodynamic Therapy in Radical CystectomyCompletedNCT03505112Not applicable
• Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]Active, not recruitingNCT03504163Phase 2
• Precise Treatment System of Biliary Malignancies Based on Special Disease DatabaseStatus unknownNCT03499782
• Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA PatientsCompletedNCT03473574Phase 2
• Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)CompletedNCT03472274Phase 2
• Intracorporeal vs Extracorporeal Urinary Diversion After Robot Assisted Radical CystectomyCompletedNCT03469362Not applicable
• Pre-Operative Single Shot Rectus Sheath BlockCompletedNCT03458598Not applicable
• Open Versus Robot Assisted Radical Cystectomy With Totally Intracorporeal Urinary Diversion.CompletedNCT03434132Not applicable
• An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.CompletedNCT03433924
• Assessment of BladderLight SurvEILlanceStatus unknownNCT03427034Phase 2/3
• Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC)Status unknownNCT03421236Phase 1
• A Study Using MRI To Assess Bladder Motion During RadiotherapyStatus unknownNCT03409029Not applicable
• A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical CystectomyCompletedNCT03404791Phase 1
• Effect of PEEP on Arterial Oxygen Partial Pressure in Elderly Patients With Lithotomy Position Using LMA Supreme™CompletedNCT03390127Not applicable
• Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial CarcinomaTerminatedNCT03389438Phase 2
• Endo-GIA Versus Endowrist Stapler in Intracorporeal Urinary Diversion in Robotic Assisted Radical CystectomyCompletedNCT03385798Not applicable
• Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic ChangesActive, not recruitingNCT03375307Phase 2
• Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBCCompletedNCT03348969Phase 4
• Trimodal Prehabilitation for Cystectomy Patients to Enhance Post-operative CareStatus unknownNCT03347045Not applicable
• Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.TerminatedNCT03335059Phase 3
• Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer (GETUG-AFU 30)Active, not recruitingNCT03333356Not applicable
• Assessment of the Uro-C Cystoscope for Use in Diagnostic Cystoscopy ProceduresStatus unknownNCT03331705
• PRS-343 in HER2-Positive Solid TumorsCompletedNCT03330561Phase 1
• Retrospective Review of FDG PET MRI Management of Patients With Muscle Invasive Bladder CancerCompletedNCT03327883
• Factors Influencing Patient Choice of Bladder Reconstruction Following Radical CystectomyCompletedNCT03325231
• First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder CarcinomaTerminatedNCT03324282Phase 2
• Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the BladderActive, not recruitingNCT03317158Phase 1/2
• Unmet Supportive Care Needs in Bladder Cancer Patients Undergoing Radical CystectomyCompletedNCT03307200
• Genomic Testing and Resulting Medical DecisionsCompletedNCT03301493
• Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder CancerWithdrawnNCT03298958Phase 3
• Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial CarcinomaActive, not recruitingNCT03291028
• A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic TumorsCompletedNCT03289962Phase 1
• A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial CancerTerminatedNCT03288545Phase 1/2
• Chemoradiotherapy for Recurrent T1G3 Bladder CancerStatus unknownNCT03274284Phase 4
• Biomarkers in Urothelial Cancer Patients Treated With PembrolizumabStatus unknownNCT03263039Phase 2
• Autophagy Bladder CancerStatus unknownNCT03254888
• Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for Thermal Ablation of Muscle Invasive Cells in Patients With Bladder TumorsWithdrawnNCT03238664Not applicable
• Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial CancerActive, not recruitingNCT03237780Phase 2
• Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for CisplatinTerminatedNCT03234153Phase 2
• The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and VomitingCompletedNCT03232541Not applicable
• A Retrospective Analysis of Spinal Anaesthesia for TURBT Procedures in Elderly PatientsStatus unknownNCT03221829
• Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of PembrolizumabCompletedNCT03212651Phase 2
• A Novel Multiplex ELISA Assay for Evaluating Patients With Gross Hematuria for Bladder CancerCompletedNCT03193528
• Immunological Response to Intravesical BCG Therapy of Superficial Bladder Cancer by Prior Administration of RUTI®CompletedNCT03191578Phase 1
• Intervention of Bladder Cancer by CAR-TTerminatedNCT03185468Phase 1/2
• In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both?CompletedNCT03174912Phase 4
• Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder CancerActive, not recruitingNCT03171025Phase 2
• To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid TumorsCompletedNCT03159585Phase 1
• Using PROMIS as Part of Routine Clinical Care for Racially Diverse Prostate and Bladder Cancer PatientsCompletedNCT03156244
• Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder CancerWithdrawnNCT03150836Phase 2
• Assessment Of Bladder Tumors Stage And Grade By Outpatient Flexible Cystoscopy Performed By Urology ResidentStatus unknownNCT03148158
• Influence of Immune Nutrition Diet on 90-Day Outcomes in Patients Undergoing Radical CystectomyStatus unknownNCT03147586Phase 4
• Role of 3 Tesla Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) for Diagnosis Bladder Cancer Grade and StageStatus unknownNCT03138837
• Storz Professional Image Enhancement System Versus White Light Imaging Assisted TURBT for Treatment of NMIBCStatus unknownNCT03138824Not applicable
• Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)CompletedNCT03133286
• Clinical Evaluation of a Test for Monitoring the Recurrence of Bladder CancerCompletedNCT03125460
• Multi Institutional Study in Patient Presenting With HematuriaStatus unknownNCT03122964
• A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)Status unknownNCT03121768
• Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG ImmunotherapyTerminatedNCT03106610Phase 1
• Urine-DNA Biomarkers in Detecting Bladder CancerCompletedNCT03066310
• Early Versus Late FDG-PET/CT in Bladder CancerCompletedNCT03065725
• The Assessment of the Feasibility of a Home Based Exercise Programme in the Older Patient Following Major SurgeryCompletedNCT03064308Not applicable
• The Effectiveness and Safety of Neoadjuvant Intravesical Mitomycin-C InstillationCompletedNCT03058757Phase 2
• Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) PatientsCompletedNCT03053635Phase 1
• Trial to Compare Robotically Assisted Radical Cystectomy With Open Radical CystectomyCompletedNCT03049410Not applicable
• Solifenacin, Levofloxacin or Lornoxicam, Which Is Ideal for Management of Intravesical Instillation BCG Side Effects?Status unknownNCT03038321Phase 4
• The Assessment of POCD After TURBT Under Spinal AnesthesiaStatus unknownNCT03029676Phase 4
• Complications of Transurethral Resection of the Bladder TumourCompletedNCT03029663
• A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic CancerCompletedNCT03027284Phase 1
• QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder CancerActive, not recruitingNCT03022825Phase 2/3
• Confocal Laser Endomicroscopy in the Lower Urinary TractCompletedNCT03013894
• Respiratory Measurement Using Infrared Camera and Respiratory Volume Monitor (ExSpiron 1Xi) for Sedation in Patients Undergoing TURP/TURB Under Spinal AnesthesiaCompletedNCT02993497Not applicable
• Transurethral En Bloc Versus Standard Resection of Bladder TumourCompletedNCT02993211Not applicable
• Bladder Tumor Biopsy Study to Improve Preoperative Determination of Stage and GradeStatus unknownNCT02992990Not applicable

← Urinary Bladder Neoplasms overview